The IPED (Investigation of Palpitations in the ED) Study (IPED)

November 6, 2019 updated by: NHS Lothian

Randomised Controlled Trial of the Use of a Smart Phone Based Event Recorder Versus Standard Care for Patients Presenting to the Emergency Department With Palpitations and Pre-syncope

Palpitations (noticeable pounding, fluttering or irregular heart beat) and pre-syncope (near blackout) are common ED problems sometimes due to an abnormal cardiac rhythm. This is difficult to diagnose as examination and electrocardiogram (ECG) are commonly normal and symptoms have usually resolved by the time the patient arrives in the ED. Diagnosing an abnormal heart rhythm as the cause of symptoms rests on capturing it on an ECG and patients are usually discharged with advice to return to the ED again for a 12-lead ECG should symptoms recur. The investigators will recruit 242 adult participants to either study or control arms. All study arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. Control arm participants will receive standard care only. Both groups will be followed-up at 90 days. The investigators believe a smart phone based event recorder will allow better and earlier diagnosis in patients with a compatible smart phone or tablet, and revolutionise ED care in this area.

Study Overview

Detailed Description

Palpitations (noticeable pounding, fluttering or irregular heart beat) and pre syncope (near blackout) are common ED problems sometimes due to an abnormal heart rhythm. Diagnosis is difficult as examination and electrocardiogram (ECG) are commonly normal and symptoms have usually resolved by the time the patient arrives in the ED. Diagnosing an abnormal heart rhythm as the cause of symptoms rests on capturing it on an ECG and patients are usually advised to return to the ED for a 12-lead ECG should symptoms recur. The investigators will recruit 242 participants aged 16 years or over presenting to the ED or Medical Assessment Unit of the Royal Infirmary of Edinburgh with an episode of palpitations or pre-syncope and who remain undiagnosed after ED assessment. The investigators will randomise and allocate participants to either study or control arms. All study arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. Control arm participants will receive standard care only. If a participant allocated to the study arm has palpitations or pre-syncope during the 90-day study period, the participant can record an ECG using the AliveCor Monitor which can be viewed by the study team. Participants will be asked to log symptoms and whether the participant was able to record an ECG during the symptoms in a participant symptom diary, which the participant will return to the research team along with the Participant satisfaction and compliance questionnaire, and smart phone based event recorder at the end of the 90 days in a pre-paid stamped, addressed envelope. Participants will be phoned at 90 days to remind the participant to complete the Participant satisfaction and compliance questionnaire and to return this with the symptom diary and smart phone based event recorder. The investigators believe a smart phone based event recorder will allow better and earlier diagnosis in patients.

Study Type

Interventional

Enrollment (Actual)

243

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Chesterfield, United Kingdom
        • Chesterfield
      • Exeter, United Kingdom
        • Royal Devon and Exeter Hospital
      • Leicester, United Kingdom, LE1 5WW
        • Leicester Royal Infirmary
      • London, United Kingdom
        • Royal London Hospital, Barts NHS Trust
      • London, United Kingdom
        • Whipps Cross Hospital, Barts NHS Trust
      • Nottingham, United Kingdom, NG7 2UH
        • Nottingham University Hospital
      • Plymouth, United Kingdom
        • Derriford Hospital
      • Reading, United Kingdom
        • Royal Berkshire Hospital
      • Taunton, United Kingdom
        • Musgrove Park Hospital
    • Midlothian
      • Edinburgh, Midlothian, United Kingdom, EH16 4SA
        • Royal Infirmary of Edinburgh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participant aged 16 years or over
  2. Participant presenting with an episode of palpitations or pre-syncope
  3. Participant's underlying ECG rhythm during these episodes remains undiagnosed after clinical assessment.

Exclusion Criteria:

  1. Prior diagnostic ECG
  2. Palpitations or pre-syncope present during an admission ECG
  3. Frequent episodes (i.e. at least once a day)
  4. Participants under 16 years of age
  5. Previous participation in the study
  6. Inability or unwilling to give informed consent.
  7. Participants with recent (i.e. within 3 months) myocardial infarction, severe heart failure (NYHA class 4) or unstable angina
  8. Participants unwilling or unable to use the AliveCor Heart Monitor and AliveECG app
  9. Participants without a compatible smart phone or tablet
  10. Participants with cardiac pacemakers or other implanted electronic devices
  11. No telephone number for follow-up
  12. Participant in custody

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study
All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
Smart phone based ECG event recorder
No Intervention: Control
All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Symptomatic Rhythm Detection up to 90 Days
Time Frame: 90 days
Symptomatic rhythm detection rate of a smart phone based event recorder for symptomatic rhythm detection versus standard care.
90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Symptomatic Cardiac Rhythm Detection up to 90 Days
Time Frame: 90 days
Symptomatic rhythm detection rate of a smart phone based event recorder for cardiac arrhythmia detection versus standard care
90 days
Time to Detection of Symptomatic Rhythm
Time Frame: 90 days
Time to detection of symptomatic rhythm using a smart phone based event recorder versus standard care
90 days
Time to Detection of Cardiac Arrhythmia Rhythm
Time Frame: 90 days
Time to detection of cardiac arrhythmia rhythm using a smart phone based event recorder versus standard care
90 days
Number of Participants Treated or (Planned for Treatment) for Cardiac Arrhythmia
Time Frame: 90 days
Number of participants treated or (planned for treatment) for cardiac arrhythmia in participants using a smart phone based event recorder versus standard care
90 days
Number of Participants Finding the AliveCor Heart Monitor Easy to Use
Time Frame: 90 days
Number of Participants answering the participant questionnaire and finding the AliveCor heart monitor easy to use
90 days
Financial Cost Per Diagnosis of Symptomatic Rhythm
Time Frame: 90 days
Financial cost per diagnosis of symptomatic rhythm using smart phone based event recorder versus standard care.
90 days
Number of Participants With Serious Outcome up to 90 Days
Time Frame: 90 days
Number of patients with all cause death and/or major adverse cardiac events (MACE; myocardial infarction, life threatening arrhythmia, insertion of pacemaker or internal cardiac defibrillator, insertion of pacing wire).
90 days
Number of Participants Completing Questionnaire
Time Frame: 90 days
Measure of questionnaire compliance - Number of participants completing questionnaire
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Matthew J Reed, MA FRCEM MD, NHS Lothian

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2016

Primary Completion (Actual)

April 1, 2018

Study Completion (Actual)

April 1, 2018

Study Registration Dates

First Submitted

March 23, 2016

First Submitted That Met QC Criteria

May 23, 2016

First Posted (Estimate)

May 26, 2016

Study Record Updates

Last Update Posted (Actual)

November 19, 2019

Last Update Submitted That Met QC Criteria

November 6, 2019

Last Verified

March 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 2016/0153
  • R15/A164 (Other Identifier: Chest Heart Stroke Scotland)
  • PG/17/63/33198 (Other Grant/Funding Number: British Heart Foundation)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Clinical Trials on AliveCor Heart Monitor

3
Subscribe